Pacira Biosciences Inc (OQ:PCRX)
Business Focus: Pharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 5401 West Kennedy Boulevard, Suite 890 TAMPA FL 33609 |
| Tel: | 1-973-4514030 |
| Website: | https://www.pacira.com |
| IR: | See website |
| Key People | ||
| Frank D. Lee Chief Executive Officer, Director | Roy Winston Chief Medical Officer and Orthopedic Franchise | Charles A. Reinhart Chief Financial Officer |
| Max Reinhardt President - Rest of World | Daryl Gaugler Chief Operating Officer | Kristen Williams Chief Administrative Officer, Secretary |
| Anthony Molloy Chief Legal and Compliance Officer | Ronald Ellis Chief Strategy Officer | Dennis Mcloughlin Chief Customer Officer | Jonathan Slonin Chief Clinical Officer |
| Business Overview |
| Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Pacira Biosciences Inc revenues increased 1% to $675M. Net income increased from $15.9M to $42M. Revenues reflect ZILRETTA segment increase of 5% to $111.1M, iovera segment increase of 29% to $19.7M. Net income benefited from Other Non Rec I/E - Non Business Activ decrease from $26.1M (expense) to $0K, Contractual interest expense decrease of 46% to $20.1M (expense). |
| Employees: | 711 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $1,458M as of Dec 31, 2023 |
| Annual revenue (TTM): | $674.98M as of Dec 31, 2023 |
| EBITDA (TTM): | $162.95M as of Dec 31, 2023 |
| Net annual income (TTM): | $41.96M as of Dec 31, 2023 |
| Free cash flow (TTM): | $139.49M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $243.86M as of Dec 31, 2023 |
| Shares outstanding: | 46,500,778 as of Feb 26, 2024 |
| Index Membership: | S&P 600 Small Cap |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.